Allegro Diagnostics Inc., a developer of medical tests for cancer, has formed an exclusive licensing deal with Boston University and the University of Utah Foundation for a molecular testing platform for early lung cancer detection.
Financial terms of the agreement were not disclosed.
The platform is designed to detect molecular response in a respiratory tract and note any sign of malignant airway cells in the lungs. Allegro has applied the platform to its genomic test product, called the BronchoGen, which it is planning to launch commercially in the first half of 2012.
Allegro announced earlier this month that it had named Michael Webb as president and CEO
of the company. Webb served previously as president and CEO of Anchor Therapeutics Inc. and in the same role at EPIX Pharmaceuticals.
Founded in 2006 by Boston University School of Medicine professors Jerome Brody and Avrum Spira, privately held Allegro Diagnostics is backed by Kodiak Venture Partners and Catalyst Health Ventures.